FDA Approved: UDENYCA — Supplemental Application (Accord BioPharma, Inc.)

View source ↗

Summary

FDA approved a supplemental application for UDENYCA (pegfilgrastim-cbqv) from Accord BioPharma, authorizing a new or expanded use for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Neutropenia
• Febrile Neutropenia

Drugs mentioned

• UDENYCA (pegfilgrastim-cbqv)

Snippet

SUPPL AP for UDENYCA (PEGFILGRASTIM-CBQV)